Intrinsic value of Altimmune - ALT

Previous Close

$3.28

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$3.28

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

Our model is not good at valuating stocks of financial companies, such as ALT.

We calculate the intrinsic value of ALT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  17
  27
  40
  58
  81
  112
  150
  197
  253
  320
  397
  486
  586
  697
  819
  953
  1,098
  1,253
  1,420
  1,596
  1,783
  1,979
  2,185
  2,401
  2,626
  2,861
  3,106
  3,361
  3,625
  3,901
Variable operating expenses, $m
  74
  113
  166
  240
  337
  461
  618
  810
  1,041
  1,314
  1,627
  1,989
  2,398
  2,853
  3,355
  3,902
  4,495
  5,132
  5,812
  6,535
  7,298
  8,103
  8,947
  9,830
  10,753
  11,715
  12,717
  13,760
  14,844
  15,970
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  74
  113
  166
  240
  337
  461
  618
  810
  1,041
  1,314
  1,627
  1,989
  2,398
  2,853
  3,355
  3,902
  4,495
  5,132
  5,812
  6,535
  7,298
  8,103
  8,947
  9,830
  10,753
  11,715
  12,717
  13,760
  14,844
  15,970
Operating income, $m
  -57
  -86
  -127
  -182
  -255
  -350
  -468
  -613
  -788
  -994
  -1,230
  -1,503
  -1,812
  -2,156
  -2,535
  -2,949
  -3,397
  -3,879
  -4,393
  -4,939
  -5,516
  -6,124
  -6,761
  -7,429
  -8,127
  -8,854
  -9,611
  -10,399
  -11,218
  -12,070
EBITDA, $m
  -52
  -81
  -121
  -175
  -247
  -339
  -456
  -598
  -770
  -972
  -1,207
  -1,476
  -1,779
  -2,117
  -2,489
  -2,896
  -3,336
  -3,808
  -4,313
  -4,849
  -5,416
  -6,013
  -6,639
  -7,295
  -7,979
  -8,693
  -9,437
  -10,211
  -11,015
  -11,851
Interest expense (income), $m
  0
  0
  1
  2
  3
  5
  8
  12
  16
  22
  28
  36
  45
  55
  67
  79
  94
  109
  126
  144
  163
  183
  205
  228
  252
  277
  303
  330
  358
  388
  418
Earnings before tax, $m
  -57
  -87
  -129
  -185
  -261
  -358
  -480
  -629
  -809
  -1,022
  -1,266
  -1,548
  -1,867
  -2,223
  -2,615
  -3,043
  -3,506
  -4,004
  -4,537
  -5,102
  -5,699
  -6,329
  -6,989
  -7,681
  -8,403
  -9,156
  -9,941
  -10,757
  -11,606
  -12,488
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -57
  -87
  -129
  -185
  -261
  -358
  -480
  -629
  -809
  -1,022
  -1,266
  -1,548
  -1,867
  -2,223
  -2,615
  -3,043
  -3,506
  -4,004
  -4,537
  -5,102
  -5,699
  -6,329
  -6,989
  -7,681
  -8,403
  -9,156
  -9,941
  -10,757
  -11,606
  -12,488

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  85
  131
  197
  285
  402
  553
  742
  975
  1,254
  1,584
  1,967
  2,405
  2,899
  3,449
  4,056
  4,718
  5,435
  6,205
  7,028
  7,901
  8,824
  9,797
  10,817
  11,885
  13,001
  14,164
  15,376
  16,637
  17,947
  19,310
Adjusted assets (=assets-cash), $m
  85
  131
  197
  285
  402
  553
  742
  975
  1,254
  1,584
  1,967
  2,405
  2,899
  3,449
  4,056
  4,718
  5,435
  6,205
  7,028
  7,901
  8,824
  9,797
  10,817
  11,885
  13,001
  14,164
  15,376
  16,637
  17,947
  19,310
Revenue / Adjusted assets
  0.200
  0.206
  0.203
  0.204
  0.201
  0.203
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
  0.202
Average production assets, $m
  29
  45
  67
  97
  137
  188
  252
  331
  426
  538
  668
  817
  985
  1,172
  1,378
  1,603
  1,847
  2,108
  2,388
  2,685
  2,998
  3,329
  3,675
  4,038
  4,417
  4,813
  5,224
  5,652
  6,098
  6,561
Working capital, $m
  9
  13
  20
  29
  41
  56
  75
  98
  127
  160
  199
  243
  293
  348
  410
  477
  549
  627
  710
  798
  891
  989
  1,093
  1,200
  1,313
  1,431
  1,553
  1,680
  1,813
  1,950
Total debt, $m
  13
  33
  62
  100
  151
  216
  298
  399
  520
  662
  828
  1,018
  1,232
  1,470
  1,733
  2,019
  2,330
  2,663
  3,019
  3,398
  3,797
  4,218
  4,660
  5,123
  5,606
  6,110
  6,634
  7,180
  7,748
  8,337
Total liabilities, $m
  37
  57
  85
  123
  174
  239
  321
  422
  543
  686
  852
  1,041
  1,255
  1,494
  1,756
  2,043
  2,353
  2,687
  3,043
  3,421
  3,821
  4,242
  4,684
  5,146
  5,629
  6,133
  6,658
  7,204
  7,771
  8,361
Total equity, $m
  48
  75
  111
  162
  228
  314
  421
  553
  711
  898
  1,116
  1,364
  1,644
  1,956
  2,300
  2,675
  3,082
  3,518
  3,985
  4,480
  5,003
  5,555
  6,133
  6,739
  7,372
  8,031
  8,718
  9,433
  10,176
  10,949
Total liabilities and equity, $m
  85
  132
  196
  285
  402
  553
  742
  975
  1,254
  1,584
  1,968
  2,405
  2,899
  3,450
  4,056
  4,718
  5,435
  6,205
  7,028
  7,901
  8,824
  9,797
  10,817
  11,885
  13,001
  14,164
  15,376
  16,637
  17,947
  19,310
Debt-to-equity ratio
  0.280
  0.450
  0.550
  0.620
  0.660
  0.690
  0.710
  0.720
  0.730
  0.740
  0.740
  0.750
  0.750
  0.750
  0.750
  0.750
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
  0.760
Adjusted equity ratio
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567
  0.567

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -57
  -87
  -129
  -185
  -261
  -358
  -480
  -629
  -809
  -1,022
  -1,266
  -1,548
  -1,867
  -2,223
  -2,615
  -3,043
  -3,506
  -4,004
  -4,537
  -5,102
  -5,699
  -6,329
  -6,989
  -7,681
  -8,403
  -9,156
  -9,941
  -10,757
  -11,606
  -12,488
Depreciation, amort., depletion, $m
  5
  5
  6
  7
  8
  10
  12
  15
  18
  22
  22
  27
  33
  39
  46
  53
  62
  70
  80
  89
  100
  111
  123
  135
  147
  160
  174
  188
  203
  219
Funds from operations, $m
  -52
  -81
  -122
  -178
  -252
  -348
  -467
  -614
  -791
  -1,000
  -1,243
  -1,521
  -1,834
  -2,184
  -2,569
  -2,989
  -3,445
  -3,934
  -4,457
  -5,012
  -5,599
  -6,218
  -6,867
  -7,546
  -8,256
  -8,996
  -9,767
  -10,569
  -11,403
  -12,269
Change in working capital, $m
  3
  5
  7
  9
  12
  15
  19
  23
  28
  33
  39
  44
  50
  56
  61
  67
  72
  78
  83
  88
  93
  98
  103
  108
  113
  118
  122
  127
  132
  138
Cash from operations, $m
  -55
  -86
  -129
  -187
  -264
  -363
  -486
  -638
  -820
  -1,034
  -1,282
  -1,565
  -1,884
  -2,239
  -2,630
  -3,056
  -3,517
  -4,012
  -4,540
  -5,101
  -5,693
  -6,316
  -6,970
  -7,654
  -8,369
  -9,114
  -9,889
  -10,696
  -11,535
  -12,407
Maintenance CAPEX, $m
  -1
  -1
  -1
  -2
  -3
  -5
  -6
  -8
  -11
  -14
  -18
  -22
  -27
  -33
  -39
  -46
  -53
  -62
  -70
  -80
  -89
  -100
  -111
  -123
  -135
  -147
  -160
  -174
  -188
  -203
New CAPEX, $m
  -10
  -16
  -22
  -30
  -40
  -51
  -64
  -79
  -95
  -112
  -130
  -149
  -168
  -187
  -206
  -225
  -244
  -262
  -279
  -297
  -314
  -330
  -347
  -363
  -379
  -395
  -412
  -428
  -445
  -463
Cash from investing activities, $m
  -11
  -17
  -23
  -32
  -43
  -56
  -70
  -87
  -106
  -126
  -148
  -171
  -195
  -220
  -245
  -271
  -297
  -324
  -349
  -377
  -403
  -430
  -458
  -486
  -514
  -542
  -572
  -602
  -633
  -666
Free cash flow, $m
  -66
  -103
  -153
  -220
  -307
  -419
  -557
  -725
  -926
  -1,160
  -1,430
  -1,736
  -2,079
  -2,459
  -2,875
  -3,327
  -3,814
  -4,335
  -4,890
  -5,477
  -6,096
  -6,746
  -7,428
  -8,140
  -8,882
  -9,656
  -10,461
  -11,299
  -12,169
  -13,073
Issuance/(repayment) of debt, $m
  13
  20
  28
  38
  51
  65
  82
  101
  121
  143
  166
  190
  214
  238
  263
  287
  310
  334
  356
  378
  400
  421
  442
  463
  483
  504
  525
  546
  568
  590
Issuance/(repurchase) of shares, $m
  74
  113
  165
  236
  327
  443
  587
  761
  968
  1,209
  1,483
  1,797
  2,147
  2,535
  2,959
  3,418
  3,913
  4,441
  5,003
  5,597
  6,223
  6,880
  7,568
  8,286
  9,036
  9,816
  10,628
  11,472
  12,349
  13,261
Cash from financing (excl. dividends), $m  
  87
  133
  193
  274
  378
  508
  669
  862
  1,089
  1,352
  1,649
  1,987
  2,361
  2,773
  3,222
  3,705
  4,223
  4,775
  5,359
  5,975
  6,623
  7,301
  8,010
  8,749
  9,519
  10,320
  11,153
  12,018
  12,917
  13,851
Total cash flow (excl. dividends), $m
  22
  30
  41
  54
  71
  90
  112
  136
  163
  192
  219
  250
  282
  314
  346
  378
  409
  439
  469
  498
  527
  555
  582
  609
  637
  664
  691
  719
  748
  777
Retained Cash Flow (-), $m
  -74
  -113
  -165
  -236
  -327
  -443
  -587
  -761
  -968
  -1,209
  -1,483
  -1,797
  -2,147
  -2,535
  -2,959
  -3,418
  -3,913
  -4,441
  -5,003
  -5,597
  -6,223
  -6,880
  -7,568
  -8,286
  -9,036
  -9,816
  -10,628
  -11,472
  -12,349
  -13,261
Prev. year cash balance distribution, $m
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -45
  -83
  -124
  -181
  -256
  -353
  -475
  -625
  -805
  -1,017
  -1,264
  -1,547
  -1,865
  -2,221
  -2,612
  -3,040
  -3,504
  -4,002
  -4,534
  -5,099
  -5,696
  -6,325
  -6,986
  -7,677
  -8,399
  -9,152
  -9,937
  -10,753
  -11,601
  -12,483
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -43
  -76
  -108
  -149
  -199
  -256
  -321
  -390
  -462
  -533
  -600
  -660
  -709
  -746
  -767
  -773
  -762
  -737
  -698
  -648
  -589
  -525
  -458
  -391
  -327
  -267
  -213
  -166
  -127
  -94
Current shareholders' claim on cash, %
  57.2
  33.0
  19.5
  11.8
  7.2
  4.5
  2.8
  1.8
  1.2
  0.8
  0.5
  0.3
  0.2
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.

FINANCIAL RATIOS  of  Altimmune (ALT)

Valuation Ratios
P/E Ratio 0.1
Price to Sales 4.4
Price to Book 1.2
Price to Tangible Book
Price to Cash Flow 0.1
Price to Free Cash Flow 0.1
Growth Rates
Sales Growth Rate -54.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 158.4%
Ret/ On Assets - 3 Yr. Avg. 30.9%
Return On Total Capital 1077.8%
Ret/ On T. Cap. - 3 Yr. Avg. 330.7%
Return On Equity 1077.8%
Return On Equity - 3 Yr. Avg. 326.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 66.7%
EBITDA Margin 4100%
EBITDA Margin - 3 Yr. Avg. 1324.2%
Operating Margin -220%
Oper. Margin - 3 Yr. Avg. -115.8%
Pre-Tax Margin 4100%
Pre-Tax Margin - 3 Yr. Avg. 1324.2%
Net Profit Margin 3880%
Net Profit Margin - 3 Yr. Avg. 1250.9%
Effective Tax Rate 5.4%
Eff/ Tax Rate - 3 Yr. Avg. 1.8%
Payout Ratio 0%

ALT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ALT stock intrinsic value calculation we used $10.738322 million for the last fiscal year's total revenue generated by Altimmune. The default revenue input number comes from 0001 income statement of Altimmune. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ALT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ALT is calculated based on our internal credit rating of Altimmune, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Altimmune.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ALT stock the variable cost ratio is equal to 445.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ALT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Altimmune.

Corporate tax rate of 27% is the nominal tax rate for Altimmune. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ALT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ALT are equal to 168.2%.

Life of production assets of 263.3 years is the average useful life of capital assets used in Altimmune operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ALT is equal to 50%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $39.395823 million for Altimmune - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 38.507 million for Altimmune is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Altimmune at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
EBS Emergent Bioso 68.44 3.72  str.sell
IBIO iBio 0.740 4.72  str.buy
PFNX Pfenex 4.77 32.23  str.buy
MRK Merck&Co 74.84 33.05  str.sell
INO Inovio Pharmac 5.03 0.35  str.sell

COMPANY NEWS

▶ Gaithersburg biotech CEO to step down   [Oct-23-18 03:05PM  American City Business Journals]
▶ Why Altimmune Stock Is Sliding Lower Today   [Oct-08-18 12:35PM  InvestorPlace]
▶ Altimmune Closes on $16.9 Million in Funding   [Oct-03-18 08:00AM  GlobeNewswire]
▶ Why Altimmune Stock Is Skyrocketing Today   [Sep-19-18 05:16PM  InvestorPlace]
▶ Altimmune, Inc. to Host Earnings Call   [Aug-15-18 06:30AM  ACCESSWIRE]
▶ Altimmune Restructures Financing Agreement   [Jun-22-18 04:15PM  GlobeNewswire]
▶ Gaithersburg biotech faces threat of stock delisting   [May-18-18 04:55PM  American City Business Journals]
▶ Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?   [May-08-18 06:03PM  Simply Wall St.]
▶ Heres Whats Moving Esperion And Altimmune, Inc.   [11:10AM  Market Exclusive]
▶ Is Altimmune Incs (NASDAQ:ALT) CEO Paid At A Competitive Rate?   [Dec-28-17 12:45PM  Simply Wall St.]
▶ ETFs with exposure to Altimmune, Inc. : December 22, 2017   [Dec-22-17 11:31AM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : December 11, 2017   [Dec-11-17 01:25PM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : November 30, 2017   [Nov-30-17 01:15PM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : November 20, 2017   [Nov-20-17 11:31AM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : October 25, 2017   [Oct-25-17 09:48AM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : October 10, 2017   [Oct-10-17 10:58AM  Capital Cube]
▶ Whats Ahead For Altimmune Inc (ALT)?   [Sep-22-17 04:56PM  Simply Wall St.]
▶ ETFs with exposure to Altimmune, Inc. : August 25, 2017   [Aug-25-17 03:44PM  Capital Cube]
▶ Maryland biotech expanding into new Gaithersburg headquarters   [Aug-23-17 07:11AM  American City Business Journals]
▶ Altimmune Closes Series B Preferred Stock Offering   [Aug-21-17 04:01PM  GlobeNewswire]
▶ [$$] Investors Give Altimmune $14.7 Million Boost Following Reverse Merger   [Aug-18-17 08:35PM  The Wall Street Journal]
▶ ETFs with exposure to Altimmune, Inc. : July 11, 2017   [Jul-11-17 02:00PM  Capital Cube]
▶ ETFs with exposure to Altimmune, Inc. : June 16, 2017   [Jun-16-17 03:21PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.